Cross-Regional Data Initiative for the Assessment and Development of Treatment for Neurological and Mental Disorders

References

• Pedersen CB, Mors O, Bertelsen A, et al. A comprehensive nationwide study of the incidence rate and lifetime risk for treated mental disorders. JAMA Psychiatry. 2014;71(5):573–581. doi:10.1001/jamapsychiatry.2014.16
   PubMed Web of Science ®Google Scholar
• Feigin VL, Nichols E, Alam T, et al. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology. 2019;18(5):459–480. doi:10.1016/S1474-4422(18)30499-X
   PubMed Web of Science ®Google Scholar
• Steel Z, Marnane C, Iranpour C, et al. The global prevalence of common mental disorders: a systematic review and meta-analysis 1980–2013. Int J Epidemiol. 2014;43(2):476–493. doi:10.1093/ije/dyu038
   PubMed Web of Science ®Google Scholar
• Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9(1):63–75.e2. doi:10.1016/j.jalz.2012.11.007
   PubMed Web of Science ®Google Scholar
• Kroenke K, Spitzer RL, Williams JB, Monahan PO, Löwe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007;146(5):317–325. doi:10.7326/0003-4819-146-5-200703060-00004
   PubMed Web of Science ®Google Scholar
• Allan CE, Valkanova V, Ebmeier KP. Depression in older people is underdiagnosed. Practitioner. 2014;258(1771):19–22, 2–3.
   Google Scholar
• Wood T, Nance E. Disease-directed engineering for physiology-driven treatment interventions in neurological disorders. APL Bioeng. 2019;3(4):040901. doi:10.1063/1.5117299
   PubMed Web of Science ®Google Scholar
• El Abdellati K, De Picker L, Morrens M. Antipsychotic treatment failure: a systematic review on risk factors and interventions for treatment adherence in psychosis. Front Neurosci. 2020;14. doi:10.3389/fnins.2020.531763
   PubMed Web of Science ®Google Scholar
• Stevović LI, Repišti S, Radojičić T, et al. Non-pharmacological interventions for schizophrenia-analysis of treatment guidelines and implementation in 12 Southeast European countries. Schizophrenia (Heidelb). 2022;8(1):10. doi:10.1038/s41537-022-00226-y
   PubMedGoogle Scholar
• Kheirbek RE, Fokar A, Little JT, et al. Association between antipsychotics and all-cause mortality among community-dwelling older adults. The Journals of Gerontology: Series A. 2019;74(12):1916–1921.
   PubMed Web of Science ®Google Scholar
• Tsai DHT, Chang WH, Lin HW, Lin SJ, Shao SC, Lai ECC. Post-discharge use of antipsychotics in patients with hospital-acquired delirium and associated risk of mortality - A population-based nested case-control study. Asian J Psychiatry. 2023;83:103533. doi:10.1016/j.ajp.2023.103533
   PubMed Web of Science ®Google Scholar
• Man KKC, Shao SC, Chang YC, et al. Cardiovascular and metabolic risk of antipsychotics in children and young adults: a multinational self-controlled case series study. Epidemiol Psychiatr Sci. 2021;30. doi:10.1017/S2045796021000494
   Web of Science ®Google Scholar
• Chung YS, Shao SC, Chi MH, et al. Comparative cardiometabolic risk of antipsychotics in children, adolescents and young adults. Eur Child Adolesc Psychiatry. 2021;30(5):769–783. doi:10.1007/s00787-020-01560-1
   PubMed Web of Science ®Google Scholar
• Huang AR, Mallet L, Rochefort CM, Eguale T, Buckeridge DL, Tamblyn R. Medication-related falls in the elderly: causative factors and preventive strategies. Drugs Aging. 2012;29(5):359–376. doi:10.2165/11599460-000000000-00000
   PubMed Web of Science ®Google Scholar
• Weston J, Bromley R, Jackson CF, et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst Rev. 2016;11(11):Cd010224. doi:10.1002/14651858.CD010224.pub2
   PubMedGoogle Scholar
• Oude Voshaar RC, Dhondt TDF, Fluiter M, et al. Study design of the Routine Outcome Monitoring for Geriatric Psychiatry & Science (ROM-GPS) project; a cohort study of older patients with affective disorders referred for specialised geriatric mental health care. BMC Psychiatry. 2019;19(1):182. doi:10.1186/s12888-019-2176-6
   PubMedGoogle Scholar
• Shao SC, Lin YH, Chang KC, et al. Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients? BMJ Open Diabetes Res Care. 2019;7(1). doi:10.1136/bmjdrc-2019-000742
   PubMed Web of Science ®Google Scholar
• Reutfors J, Cesta CE, Cohen JM, et al. Antipsychotic drug use in pregnancy: a multinational study from ten countries. Schizophr Res. 2020;220:106–115. doi:10.1016/j.schres.2020.03.048
   PubMed Web of Science ®Google Scholar
• Lai ECC, Man KKC, Chaiyakunapruk N, et al. Brief report: databases in the Asia-Pacific region: the potential for a distributed network approach. Epidemiology. 2015;26(6):815–820. doi:10.1097/EDE.0000000000000325
   PubMed Web of Science ®Google Scholar
• Lai ECC, Stang P, Kao Yang YH, Kubota K, Wong ICK, Setoguchi S. International multi-database pharmacoepidemiology: potentials and pitfalls. Curr Epidemiol Rep. 2015;2(4):229–238. doi:10.1007/s40471-015-0059-z
   Google Scholar
• Man KKC, Shao SC, Chaiyakunapruk N, et al. Metabolic events associated with the use of antipsychotics in children, adolescents and young adults: a multinational sequence symmetry study. Eur Child Adolesc Psychiatry. 2022;31(1):99–120. doi:10.1007/s00787-020-01674-6
   PubMed Web of Science ®Google Scholar
• Ilomäki J, Bell JS, Chan AYL, et al. Application of healthcare ‘Big Data’ in CNS drug research: the example of the Neurological and mental health Global Epidemiology Network (NeuroGEN). CNS Drugs. 2020;34(9):897–913. doi:10.1007/s40263-020-00742-4
   PubMed Web of Science ®Google Scholar
• Leung TYM, Chan AYL, Chan EW, et al. Short- and potential long-term adverse health outcomes of COVID-19: a rapid review. Emerg Microbes Infect. 2020;9(1):2190–2199. doi:10.1080/22221751.2020.1825914
   PubMed Web of Science ®Google Scholar
• Man KKC, Chan EW, Ip P, et al. Prenatal antidepressant use and risk of attention-deficit/hyperactivity disorder in offspring: population based cohort study. BMJ. 2017;357:j2350. doi:10.1136/bmj.j2350
   PubMedGoogle Scholar
• Ilomäki J, Lai ECC, Bell JS. Using clinical registries, administrative data and electronic medical records to improve medication safety and effectiveness in dementia. Curr Opin Psychiatry. 2020;33(2):163–169. doi:10.1097/YCO.0000000000000579
   PubMed Web of Science ®Google Scholar
• Lai ECC, Ryan P, Zhang Y, et al. Applying a common data model to Asian databases for multinational pharmacoepidemiologic studies: opportunities and challenges. Clin Epidemiol. 2018;10:875–885. doi:10.2147/CLEP.S149961
   PubMed Web of Science ®Google Scholar
• Huang WC, Yang ASH, Tsai DHT, Shao SC, Lin SJ, Lai ECC. Association between recently raised anticholinergic burden and risk of acute cardiovascular events: nationwide case-case-time-control study. BMJ. 2023;382:e076045. doi:10.1136/bmj-2023-076045
   PubMedGoogle Scholar
• Raman SR, Man KKC, Bahmanyar S, et al. Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases. Lancet Psychiatry. 2018;5(10):824–835. doi:10.1016/S2215-0366(18)30293-1
   PubMed Web of Science ®Google Scholar
• Hsieh CY, Su CC, Shao SC, et al. Taiwan’s national health insurance research database: past and future. Clin Epidemiol. 2019;11:349–358. doi:10.2147/CLEP.S196293
   PubMed Web of Science ®Google Scholar
• Lai ECC, Chang CH, Kao Yang YH, Lin SJ, Lin CY. Effectiveness of sulpiride in adult patients with schizophrenia. Schizophr Bull. 2013;39(3):673–683. doi:10.1093/schbul/sbs002
   PubMed Web of Science ®Google Scholar
• Wang Z, Chan AYL, Coghill D, et al. Association between prenatal exposure to antipsychotics and attention-deficit/hyperactivity disorder, autism spectrum disorder, preterm birth, and small for gestational age. JAMA Intern Med. 2021;181. doi:10.1001/jamainternmed.2021.4571
   Web of Science ®Google Scholar
• Su CC, Lai ECC, Kao Yang YH, et al. Incidence, prevalence and prescription patterns of antipsychotic medications use in Asia and US: a cross-nation comparison with common data model. J Psychiatr Res. 2020;131:77–84. doi:10.1016/j.jpsychires.2020.08.025
   PubMed Web of Science ®Google Scholar
• Krysinska K, Sachdev PS, Breitner J, Kivipelto M, Kukull W, Brodaty H. Dementia registries around the globe and their applications: a systematic review. Alzheimers Dement. 2017;13(9):1031–1047. doi:10.1016/j.jalz.2017.04.005
   PubMed Web of Science ®Google Scholar
• Washington DL, Sun S, Canning M. Creating a sampling frame for population-based veteran research: representativeness and overlap of VA and department of defense databases. J Rehabil Res Dev. 2010;47(8):763–771. doi:10.1682/JRRD.2009.08.0127
   PubMedGoogle Scholar
• Shao SC, Chan YY, Kao Yang YH, et al. The Chang Gung Research Database—a multi-institutional electronic medical records database for real-world epidemiological studies in Taiwan. Pharmacoepidemiol Drug Saf. 2019;28(5):593–600. doi:10.1002/pds.4713
   PubMed Web of Science ®Google Scholar
• Sung SF, Chen SC, Hsieh CY, Li CY, Lai ECC, Hu YH. A comparison of stroke severity proxy measures for claims data research: a population-based cohort study. Pharmacoepidemiol Drug Saf. 2016;25(4):438–443. doi:10.1002/pds.3944
   PubMed Web of Science ®Google Scholar
• Shao SC, Lai ECC, Chen YH, Chan YY, Chen HY. Management of irrational self-purchase of hydroxychloroquine during the COVID-19 pandemic: experiences from the largest healthcare system in Taiwan. J Patient Saf. 2021;17(1):e43–e4. doi:10.1097/PTS.0000000000000795
   PubMed Web of Science ®Google Scholar
• Fortuny J, Gilsenan A, Cainzos-Achirica M, et al. Study design and cohort comparability in a study of major cardiovascular events in new users of prucalopride versus polyethylene glycol 3350. Drug Saf. 2019;42(10):1167–1177. doi:10.1007/s40264-019-00836-z
   PubMed Web of Science ®Google Scholar
• Li Z, Kormilitzin A, Fernandes M, et al. Validation of UK Biobank data for mental health outcomes: a pilot study using secondary care electronic health records. Int J Med Inform. 2022;160:104704. doi:10.1016/j.ijmedinf.2022.104704
   PubMed Web of Science ®Google Scholar
• Socrates A, Maxwell J, Glanville KP, et al. Investigating the effects of genetic risk of schizophrenia on behavioural traits. NPJ Schizophrenia. 2021;7(1):. doi:10.1038/s41537-020-00131-2
   PubMed Web of Science ®Google Scholar
• Trifirò G, Coloma PM, Rijnbeek PR, et al. Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how? J Intern Med. 2014;275(6):551–561. doi:10.1111/joim.12159
   PubMed Web of Science ®Google Scholar
• Gini R, Sturkenboom MCJ, Sultana J, et al. Different strategies to execute multi-database studies for medicines surveillance in real-world setting: a reflection on the European model. Clin Pharmacol Ther. 2020;108(2):228–235. doi:10.1002/cpt.1833
   PubMed Web of Science ®Google Scholar
• FitzHenry F, Resnic FS, Robbins SL, et al. Creating a common data model for comparative effectiveness with the observational medical outcomes partnership. Appl Clin Inform. 2015;6(3):536–547. doi:10.4338/ACI-2014-12-CR-0121
   PubMed Web of Science ®Google Scholar
• Weeks J, Pardee R. Learning to share health care data: a brief timeline of influential common data models and distributed health data networks in U.S. health care research. EGEMS (Washington, DC). 2019;7:4. doi:10.5334/egems.279
   PubMedGoogle Scholar
• Thurin NH, Pajouheshnia R, Roberto G, et al. From inception to ConcePTION: genesis of a network to support better monitoring and communication of medication safety during pregnancy and breastfeeding. Clin Pharmacol Ther. 2022;111(1):321–331. doi:10.1002/cpt.2476
   PubMed Web of Science ®Google Scholar
• Anderson TS, Ayanian JZ, Souza J, Landon BE. Representativeness of participants eligible to be enrolled in clinical trials of aducanumab for Alzheimer disease compared with medicare beneficiaries with Alzheimer disease and mild cognitive impairment. JAMA. 2021;326(16):1627–1629. doi:10.1001/jama.2021.15286
   PubMed Web of Science ®Google Scholar
• Weinmann S, Roll S, Schwarzbach C, Vauth C, Willich SN. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr. 2010;10:. doi:10.1186/1471-2318-10-14
   PubMed Web of Science ®Google Scholar
• Yuan Q, Wang CW, Shi J, Lin ZX. Effects of Ginkgo biloba on dementia: an overview of systematic reviews. J Ethnopharmacol. 2017;195:1–9. doi:10.1016/j.jep.2016.12.005
   PubMed Web of Science ®Google Scholar
• Shao SC, Lai ECC, Huang TH, et al. The Chang Gung Research Database: multi-institutional real-world data source for traditional Chinese medicine in Taiwan. Pharmacoepidemiol Drug Saf. 2021;30(5):652–660. doi:10.1002/pds.5208
   PubMed Web of Science ®Google Scholar
• Koponen M, Paakinaho A, Lin J, Hartikainen S, Tolppanen AM. Identification of drugs associated with lower risk of Parkinson’s disease using a systematic screening approach in a nationwide nested case-control study. Clin Epidemiol. 2022;14:1217–1227. doi:10.2147/CLEP.S381289
   PubMed Web of Science ®Google Scholar
• Paakinaho A, Koponen M, Tiihonen M, Kauppi M, Hartikainen S, Tolppanen A-M. Disease-modifying antirheumatic drugs and risk of Parkinson disease. Nested Case-Control Study People Rheumatoid Arthritis. 2022;98(12):e1273–e81.
   Google Scholar
• Sunnarborg K, Tiihonen M, Huovinen M, Koponen M, Hartikainen S, Tolppanen AM. Association between different diabetes medication classes and risk of Parkinson’s disease in people with diabetes. Pharmacoepidemiol Drug Saf. 2022;31(8):875–882. doi:10.1002/pds.5448
   PubMed Web of Science ®Google Scholar